<DOC>
	<DOCNO>NCT00446433</DOCNO>
	<brief_summary>A Multicenter , Randomized , Double-Blind , Placebo-Controlled , Parallel-Group Study Evaluate Safety Efficacy CC-5013 Treatment Adolescents Adults Moderately Severe Crohn 's Disease</brief_summary>
	<brief_title>A Study Evaluate CC-5013 Treatment Adolescents Adults With Moderately Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>1 . Male female subject &gt; 12 &lt; 75 year age . 2 . Adolescent adult female subject must nonchildbearing potential ( hysterectomy ) use one highly effective method ( e.g. , IUD , hormonal contraception , tubal ligation ) birth control entire study . Abstinence consider acceptable method birth control adolescent female age 1217 year sexually active investigator feel compliant requirement 12week treatment period . Female subject postmenopausal must 24 continuous month amenorrhea . 3 . Negative pregnancy test females child bear potential . 4 . A history Crohn 's Disease ( CD ) great 1year duration diagnose documented standard clinical , radiographic , endoscopic , histopathological criterion . 5 . Signs symptom moderately severe CD define Crohn 's Disease Activity Index ( CDAI ) score &gt; 220 &lt; 400 . 6 . Normal thyroid function document normal TSH ( thyroid stimulate hormone ) . 7 . The subject 's treatment CD must unchanged , describe : The start date medication list must least 4 week prior randomization , dose must unchanged least 2 week prior visit . Medication dose may decrease increase throughout study . If currently use agent , stop date previous treatment agent must least 4 week prior randomization . The medication : oral systemic corticosteroid metronidazole ( Flagyl® ) sulfasalazine oral mesalamine oral olsalazine topical rectal therapy corticosteroid mesalamine 8 . The start date medication list must least 3 month ( 12 week ) prior randomization , dose must unchanged least 4 week . Medication dose may decrease increase throughout study . If currently use agent , stop date previous treatment agent must least 6 week prior randomization . The medication : azathioprine ( AZA ) 6mercaptopurine ( 6 MP ) methotrexate 9 . Subject 's screening laboratory test result must meet following criterion : hemoglobin &gt; 8.5 g/dL . white blood cell ( WBC ) &gt; 3.5 x 109 / L. neutrophil &gt; 1.5 x 109/L lymphocyte &gt; 0.5 x 109/L . platelet &gt; 100 x 109 / L. bilirubin , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , alkaline phosphate level must two time upper limit normal range . serum albumin &gt; 3.2 mg /dL adult ( 1875 ) serum albumin &gt; 2.8 mg/dL adolescent age 1217. serum creatinine &lt; 2.0 mg/dL 10 . Subjects must able adhere study visit schedule protocol requirement . 11 . The subject must understand voluntarily sign informed consent document . Adolescent subject 18 year age must parent/guardian consent evidenced signature consent form well assent , evidenced signature consent form . 12 . The subject must least 25 kg ( 55 lb ) . 1 . Pregnancy lactation . 2 . Predisposition cardiac arrhythmias history clinically significant cardiac disease . 3 . Diagnosis ulcerative colitis . 4 . CD limit stomach proximal small intestine . 5 . Known severe fix symptomatic stenosis stricture small large intestine . 6 . Current evidence bowel obstruction , history within 3 month precede randomization confirm objective radiographic endoscopic evidence stricture result obstruction ( dilation bowel proximal stricture observe upon barium enema inability traverse stricture endoscopy . 7 . Subjects undergone proctocolectomy total colectomy ileorectal anastomosis ; segmental colectomy permit . 8 . Colostomy ileostomy . 9 . Subjects fulminant disease require parenteral steroid treatment , hospitalization , felt imminent need surgery , i.e . toxic megacolon , active gastrointestinal bleeding , history significant ulcer disease and/or esophagitis , peritonitis , intestinal obstruction , perforation , intraabdominal abscess require surgical drainage . 10 . Subjects require intravenous nutritional support total parenteral nutrition ( TPN ) /partial parenteral nutrition ( PPN ) provide &gt; 50 % total daily caloric intake . 11 . Subjects enteral nutrition elemental semielemental formula comprise 50 % total daily caloric intake . For adolescent age 1217 , subject enternal nutrition elemental semielemental formula comprise 75 % total daily caloric intake . 12 . Current sign symptom severe , progressive , uncontrolled renal , hepatic , hematological , endocrine ( include thyroid document abnormal TSH ) , pulmonary , cardiac , neurological , cerebral disease , include follow specific exclusion : uncontrolled diabetes , unstable ischemic heart disease , uncontrolled recent seizure , autoimmune disease related inflammatory bowel disease , chronic respiratory insufficiency , recent cerebral vascular accident ( within 2 month randomization ) . 13 . Serious infection history opportunistic infection ; less serious infection within 3 month randomization , acute upper respiratory tract infection ( cold ) uncomplicated urinary tract infection permit discretion Investigator . The follow specific exclusion : Chronic hepatitis B C Documented HIV infection , ARC ( AIDS relate complex ) , AIDS , immune deficiency . 14 . Stool examination positive enteric pathogen ( include Clostridium difficile ) , pathogenic ovum , parasites . 15 . Concomitant recent medication use follow : Treatment therapeutic agent target reduce TNFa , e.g. , CC1088 , thalidomide , cyclosporine , pentoxifylline within 4 week randomization , mycophenolate ( Cellcept ) , infliximab ( Remicadeä ) , Enbrelä , FK506 ( Tacrolimus ) within 8 week randomization Treatment interleukin2 10 immunomodifier agent within 24 week randomization . Requirement systemic corticosteroid therapy disease ( ) , e.g. , asthma . Inhaled steroid treat asthma acceptable protocol . Subjects receive anticoagulant therapy ( total daily aspirin dose 325 mg less ) . Subjects receive non CDdirected antibiotic therapy within 2 week randomization . CDdirected antibiotic therapy , example ciprofloxacin metronidazole , acceptable provide dose stable 2 week prior randomization . Subjects received investigational drug within 30 day randomization . 16 . Subjects history malignancy , except basal cell squamous cell carcinoma skin cervical carcinoma situ . 17 . Dysplasia ( lowgrade highgrade ) colon/small bowel within last 5 year prior screen . 18 . Subjects , judgment Investigator , unwilling unable comply protocolrelated assessment procedure , include completion daily diary . 19 . History alcohol drug abuse within 1 year randomization , condition associate poor compliance . 20 . Subjects multiple venipuncture feasible due poor tolerability lack easy access . 21 . Any condition , opinion Investigator , place subject unacceptable risk he/she participate study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>